Skip to main content

Table 3 HAE-QoL scores and variations

From: Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study

HAE-QoL score Basal After 6 months (visit 3) After 12 months (visit 4)
Total (N = 15) 88.6 ± 24.4 (75─106) 95.1 ± 24 (85─103) 94 ± 27.6 (86─113)
 Physical functioning and health 15.1 ± 4 (12─16) 15.8 ± 4.7 (15─19) 16 ± 4 (15─20)
 Disease related stigma 10.7 ± 3.5 (8─14) 10.7 ± 4 (8─15) 10.7 ± 3.9 (9─14)
 Emotional role and social functioning 14.4 ± 3.4 (14─16) 14.4 ± 4.4 (14─17) 14.9 ± 4.5 (15─18)
 Concern about offspring 6.2 ± 3.1 (3─9) 7.6 ± 2.6 (6─10) 7.1 ± 3.1 (4─10)
 Perceived control over illness 11.3 ± 4 (9─15) 12.8 ± 3.9 (11─14) 13.1 ± 4.1 (11─16)
 Mental health 14.7 ± 5.4 (11─20) 16.5 ± 5.8 (14─21) 15.2 ± 5.2 (12─18)
 Treatment difficulties 16.3 ± 5.3 (15─20) 17.2 ± 5.4 (15─22) 16.9 ± 5.5 (14─22)
Differences in HAE-QoL score between the visits Visit 3 vs 1 p Visit 4 vs 1 p Visit 4 vs 3 p
Total (N = 15) 6.4 ± 13.5 (4─14) 0.49 5.4 ± 21.4 (−4─15) 0.59 −1.1 ± 13.4 (−6─3) 0.91
 Physical functioning and health 0.7 ± 2.8 (−1─3) 0.67 0.9 ± 3 (−1─4) 0.55 0.2 ± 2.2 (0─1) 0.90
 Disease related stigma 0 ± 2.3 (−1─1) 1 0 ± 2.8 (−1─1) 1 0 ± 1.4 (−1─0) 1
 Emotional role and social functioning 0.1 ± 2.7 (−1─2) 0.71a 0.5 ± 2.7 (−1─2) 0.36a 0.4 ± 1.6 (−1─2) 0.69a
 Concern about offspring 1.4 ± 2.3 (0─1) 0.20a 0.9 ± 3.1 (0─1) 0.34a −0.5 ± 2 (0─0) 0.87a
 Perceived control over illness 1.5 ± 2.9 (0─4) 0.32 1.9 ± 3.9 (−1─4) 0.24 0.4 ± 2.9 (− 1─3) 0.82
 Mental health 1.8 ± 3.9 (1─4) 0.41 0.5 ± 4.7 (− 2─4) 0.80 −1.3 ± 4.4 (− 2─0) 0.54
 Treatment difficulties 0.9 ± 4 (0─3) 0.65 0.6 ± 5.8 (0─2) 0.75 −0.3 ± 4.6 (−1─0) 0.89
  1. HAE-QoL scores and variations were elaborated from the analysis of the questionnaires administered at visits 1, 3 and 4
  2. p: p-value; aTest di Wilcoxon (violation of the assumption of normality)